WILMINGTON, Mass., June 11, 2015 /PRNewswire/ -- Implant
Sciences Corporation (OTCQB: IMSC), a leading manufacturer of
explosives trace detection (ETD) and drugs trace detection
solutions for homeland security applications, today announced that
it has signed a contract for up to 304 of its QS-B220 desktop
explosives trace detectors across 17 regional airports in
France. The first 106 units are
committed to being delivered over the next several months.
Additional units are expected to be delivered through fiscal year
2016 and 2017. The sale was made through the Company's in-country,
full-service distributor, Hi-Tech Detection Systems (HTDS).
"The fact that our QS-B220 had STAC certification prior to the
creation ECAC standards gave us additional insight into the French
aviation market. Our systems are highly regarded in the region, and
we believe that procurement agents look to the QS-B220's value and
performance and view the choice of selecting our unit as a 'smart'
decision," said Dr. Darryl Jones,
Implant Sciences' Vice President of Global Sales and
Marketing. "We are very proud of the fact that this is the
second major victory for us in France."
"HTDS is an excellent long-term partner in France. Their ability to provide superior
in-country support, such as service and training, makes them a
strong ally and value-add for Implant Sciences. Their sound
customer support capabilities also proved to be a deciding factor
for this procurement," stated Richard
Nelson, Implant Sciences' General Manager, EMEA.
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly
detect and identify trace amounts of a wide variety of military,
commercial, and homemade explosives. With significantly lower
maintenance requirements than competing systems, the QS-B220 can be
deployed for a much lower total cost of ownership than other
approved products. Featuring a radioactive material-free design,
push-button maintenance and diagnostics, and a patented inCalâ„¢
internal automatic calibration system, the QS-B220 brings new
levels of performance and convenience to desktop trace detection
users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing
advanced detection capabilities to counter and eliminate the
ever-evolving threats from explosives and drugs. The Company's team
of dedicated trace detection experts has developed proprietary
technologies used in its commercial products, thousands of which
have been sold across more than 60 countries worldwide. The
Company's ETDs have received approvals and certifications from
several international regulatory agencies including the TSA in the
U.S., ECAC in Europe, CAAC and the
Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the
Interior. It has also received the GSN Homeland Security Award for
"Best Explosives Detection Solution" two years in a row (2013 and
2014). All Implant Sciences products are recognized as
Qualified Anti-Terrorism Technologies by the Department of Homeland
Security. For further details on the Company and its products,
please visit the Company's website at www.implantsciences.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and any statements of employees,
representatives and partners of Implant Sciences Corporation (the
"Company") related thereto contain or may contain certain
"forward-looking statements," as that term is defined in the
Private Securities Litigation Reform Act of 1995. Such
statements may include, without limitation, statements with respect
to the Company's plans, objectives, projections, expectations and
intentions and other statements identified by words such as
"projects," "may," "will," "could," "would," "should," "believes,"
"expects," "anticipates," "estimates," "intends," "plans,"
"potential" or similar expressions. Such statements are based
on management's current expectations and are subject to significant
risks and uncertainties (many of which are beyond the Company's
control) that could cause the Company's actual results to differ
materially from the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the risks that
there is no guaranty that the Transportation Security
Administration (TSA) or any other U.S. or foreign government and
law enforcement agencies or commercial consumers will purchase any
of our explosives detection products or that any new products we
may develop will be accepted by the TSA or by such other
governments, agencies or consumers; economic, political and other
risks associated with international sales and operations could
adversely affect our sales; our business is subject to intense
competition and rapid technological change, and our ability to
generate revenue and profit will depend on our ability to develop
and introduce new products; and other risks and uncertainties
described in our filings with the Securities and Exchange
Commission, including our most recent Forms 10-K, 10-Q and
8-K. In light of these risks and uncertainties, readers are
cautioned that actual results may differ significantly from those
described or anticipated in the forward-looking statements.
The Company undertakes no obligation to publicly update any
forward-looking statements, whether as a result of new information,
future presentations or otherwise, except as required by applicable
law.
Contact:
Implant Sciences Corporation
Company Contact:
Robert Liscouski
978-752-1700 x 116
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/up-to-304-additional-qs-b220s-sold-to-french-airports-as-implant-sciences-deepens-its-foothold-in-eu-300097733.html
SOURCE Implant Sciences Corporation